Victory Capital Management Inc. Has $94.44 Million Stock Holdings in QIAGEN N.V. (NYSE:QGEN)

Victory Capital Management Inc. trimmed its position in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 1.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,352,068 shares of the company's stock after selling 37,797 shares during the quarter. Victory Capital Management Inc. owned approximately 1.06% of QIAGEN worth $94,436,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Edgestream Partners L.P. acquired a new position in shares of QIAGEN during the 1st quarter valued at about $3,029,000. New York State Common Retirement Fund increased its stake in QIAGEN by 3.0% during the 1st quarter. New York State Common Retirement Fund now owns 125,126 shares of the company's stock worth $5,024,000 after buying an additional 3,623 shares during the period. Banque Pictet & Cie SA increased its position in shares of QIAGEN by 20.7% during the first quarter. Banque Pictet & Cie SA now owns 86,207 shares of the company's stock worth $3,415,000 after acquiring an additional 14,792 shares during the last quarter. Beverly Hills Private Wealth LLC purchased a new stake in QIAGEN during the 1st quarter worth approximately $299,000. Finally, Crossmark Global Holdings Inc. increased its stake in shares of QIAGEN by 13.1% in the first quarter. Crossmark Global Holdings Inc. now owns 43,503 shares of the company's stock worth $1,747,000 after buying an additional 5,034 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

QIAGEN Stock Performance

Shares of QGEN stock traded up $0.11 during trading hours on Friday, reaching $48.35. 2,726,997 shares of the company's stock were exchanged, compared to its average volume of 1,224,212. QIAGEN N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The company has a quick ratio of 2.83, a current ratio of 3.37 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $10.75 billion, a P/E ratio of 20.86, a P/E/G ratio of 2.45 and a beta of 0.68. The business has a fifty day moving average price of $45.95 and a 200-day moving average price of $42.98.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. QIAGEN had a net margin of 4.68% and a return on equity of 14.61%. The business had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same quarter in the previous year, the firm posted $0.44 earnings per share. QIAGEN's revenue was up 5.2% compared to the same quarter last year. Analysts predict that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

QIAGEN Dividend Announcement

The company also recently declared a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a $0.25 dividend. The ex-dividend date was Wednesday, July 2nd. This represents a yield of 0.52%. QIAGEN's dividend payout ratio (DPR) is 62.50%.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of recent research reports. Barclays assumed coverage on shares of QIAGEN in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. Robert W. Baird increased their price objective on shares of QIAGEN from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Bank of America boosted their price objective on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Redburn Atlantic cut QIAGEN from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Finally, Wall Street Zen upgraded shares of QIAGEN from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $49.40.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.